New humanised mouse model provides insight into immunotherapy resistance

12 Jan 2021
New humanised mouse model provides insight into immunotherapy resistance

Scientists at The Wistar Institute have created an advanced humanised immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

It has revealed a central role for mast cells. These findings were published today in the journal Nature Communications.

Checkpoint inhibitors revolutionised therapeutic options for advanced melanoma.

However, only a fraction of patients respond to this treatment and some relapse due to reemergence of therapy-resistant lesions.

"To better understand why some cancers do not respond or become resistant to checkpoint therapies, we need more preclinical models that mimic the human tumour immune environment," said Rajasekharan Somasundaram, Ph.D., a member of The Wistar Institute Melanoma Research Center, who is the first and corresponding author of the paper.

Due to critical differences in the murine and human immune systems, mouse models do not allow the study of immune mechanisms that are uniquely human.

"Humanised" mouse models are widely used to mimic the human immune system in mice.

Wistar's new humanised mouse model relies upon transplanted human stem cells and tissues that have been uniquely engineered to produce combinations of human cytokines that result in a more physiologically relevant model system for evaluating new immuno-oncology therapies and effective treatments targeting the tumour microenvironment.

"Our novel humanised mouse model has a longer life span and allowed us to study treatment responses to immunotherapies after human tumour transplant," said Somasundaram, who was part of a Wistar team led by Meenhard Herlyn, D.V.M., D.Sc., professor in The Wistar Institute Cancer Center, director of The Wistar Institute Melanoma Research Center, and a co-senior author on the study.

Researchers transplanted human metastatic melanoma cell lines into their humanised mouse model and treated them with anti-PD-1 antibody therapy.

By studying immune cell infiltration into the tumours, Somasundaram and colleagues observed an abundance of infiltrated mast cells in anti-PD-1-treated tumours.

Mast cells are an immune cell found throughout the body, especially in the skin and mucosa, where they serve as a first line of defense against pathogens.

In samples from melanoma patients receiving immune checkpoint therapies, the team saw the same higher abundance of mast cells in non-responding tumours.

The authors showed that combining anti-PD-1 therapy with small molecule inhibitors able to deplete mast cells caused complete regression of tumours in mice and prolonged survival in comparison with mice receiving either treatment.

Importantly, mice that reached remission did not show any signs of recurrence for four weeks after cessation of therapy and developed memory T cell response against melanoma tumours.

"Our results suggest that mast cells are associated with resistance to anti-PD-1 therapy, and that depleting mast cells is beneficial to immune checkpoint therapy responses," said Herlyn.

"This warrants further investigation into the development of new combined immunotherapy approaches with small molecule inhibitors for the treatment of melanoma patients."